期刊文献+

黄体酮在奶牛体内的药物动力学 被引量:4

The Pharmacokinetics of Progesterone in Cows
下载PDF
导出
摘要 分析黄体酮(Progesterone)在奶牛体内的药物代谢动力学过程。试验前,奶牛进行摘除卵巢手术,术后30 d单剂量肌肉注射不孕奶牛催乳注射液(含黄体酮与苯甲酸雌二醇),120 h内不同时间15次颈静脉采血,用放射免疫分析法(RIA)测定血清黄体酮浓度。结果表明,黄体酮在奶牛体内的药物动力学配置属于有吸收因素二室模型,其药时曲线方程为C=5.0600e-0.0581t+1.5360e-0.0091t6.5960e-0.3078t。消除相半衰期为(81.6135±24.3323)h,药时曲线下面积为(230.6931±48.5255)ng/(mL.h),达峰浓度为(3.798±1.083)ng/mL,达峰时间为(8.0±1.9)h。黄体酮在奶牛体内分布广泛,消除缓慢。 Pharmacokinetics parameters of progesterone in cows were calculated so as to provide proof to veterinary clinic. Four cows after ovariectomy were treated with a single dosage of injection of progesterone and estradiol benzoate intramuscular injection, while the blood samples were collected from vein within 120 hours after giving drug. The concentrations of Progesterone in serum were determined by radioimmunoassay (RIA). The two-compartment model with absorption factor adequately described concentrations of Progesterone in serum disposition and the best concentration-time equation was C=5.0600e^0.0581t+1.5360e^0.0091t-6.5960e^0.3078t. The primary pharmacokinetics parameters of progesterone in cows were as follows: Half-time of elimination phase (t1/2β) was (81. 61354±24. 3323) h, Area under curve (AUC) was (230. 6931±48. 5255) ng · mL^-1 · h, Peak concentration (Cmax) was (3. 7984±1. 083) ng/mL, and Time to peak (Tmax) was (8.0±1. 9) h. The distribution of progesterone in cows was abroad, and the elimination of progesterone in cows was slowly.
出处 《西北农业学报》 CAS CSCD 北大核心 2009年第3期47-50,共4页 Acta Agriculturae Boreali-occidentalis Sinica
关键词 黄体酮 奶牛 药物代谢动力学 Progesterone Cow Pharmacokinetics
  • 相关文献

参考文献8

二级参考文献25

  • 1蒋新国,朱芳海,奚念朱,李征.HPLC测定甲磺酸培氟沙星血药浓度及其应用于人体生物利用度研究[J].中国药学杂志,1994,29(7):410-413. 被引量:6
  • 2李华,陆红,张朴,赵彩云,李家泰.甲磺酸培氟沙星多次给药的药代动力学与合理给药方案研究[J].中国药学杂志,1996,31(1):37-40. 被引量:6
  • 3陈勇,李元光,戈京国,韩凤梅,袁倬斌.甲磺酸培氟沙星的极谱研究与测定[J].分析试验室,1996,15(5):76-78. 被引量:43
  • 4曾衍霖.药物动力学中的第二个计算问题—原始数据的权量与线数字模型房室的确定[J].药学学报,1980,.
  • 5Massia R, Miranda P, Valdes P, et al, Prergistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women. Contraception,1999, 60(1): 9-14.
  • 6Diaz S, Reyes MV, Zepeda A, et al. Norplant implants and progesterone vaginal rings do not affect maternal bone turnover and density during lactation and after weaning. Hum Reprod, 1999, 14(10): 2 499-505.
  • 7Croxatto HB & Diaz S. The place of progesterone in human contraception. J Steroid Biochem, 1987, 27(5): 991-4.
  • 8Diaz S, Jackanicz TM, Herreros C, et aL Fertility regulation in nursing women:Ⅶ. Progesterone plasma levels and contraceptive efficacy of a progesterone-releasing vaginal ring. Contraception, 1985, 32(6): 603-22.
  • 9Croxatto HB & Diaz S. Progesterone vaginal rings for contraception during breastfeeding. In: Runnebaum B, Rabe T & Kiesel L (eds). Advances in Gynecological and Obstetric Research Series.Vol. 2: Female contraception and male fertility regulation. New Jersey: The Parthenon Publishing Group,1991, p.245-52.
  • 10Diaz S, Miranda P, Brandeis A, et al. Mechanism of action of progesterone as contraceptive for lactating women. In:Seppala M & Hamberger L (eds). Frontiers in Human Reproduction. New York: The New York Academy of Sciences,1991, p.11-21.

共引文献16

同被引文献43

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部